Behavior of circulating CD4+CD25+Foxp3+ regulatory T cells in colon cancer patients undergoing surgery

Journal of Clinical Immunology

Volumn 31, Issue 6, 2011, Pages 1095-1104

  Sellitto, Ausilia ^a   Galizia, Gennaro ^a   De Fanis, Umberto ^a   Lieto, Eva ^a   Zamboli, Anna ^a   Orditura, Michele ^a   De Vita, Ferdinando ^a   Giunta, Riccardo ^a   Lucivero, Giacomo ^a   Romano, Ciro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

CD4+CD25+Foxp3+ regulatory T cells; Colon cancer; Immunoevasion; Surgery; Tregs

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOREGULATION; IN VIVO STUDY; LIVER METASTASIS; LYMPHOCYTE FUNCTION; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR ESCAPE; TUMOR IMMUNOLOGY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD4; CARCINOMA; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOPLASM STAGING; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84857056313     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9585-8     Document Type: Article

References (45)

1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137-46. (Pubitemid 46718398)
2. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppres-sive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-96. (Pubitemid 46697910)
3. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704-15.
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-70.
5. Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011;127:1329-41.
6. Grulich AE. Cancer: the effects of HIV and antiretroviral therapy, and implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS. 2009;4:183-7.
7. Clifford GM, Franceschi S. Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol. 2009;5:669-78.
8. Blaes AH, Morrison VA. Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Rev Hematol. 2010;3:35-44.
9. Roithmaier S, Haydon AM, Loi S, Esmore D, Griffiths A, Bergin P, et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant. 2007;26:845-9. (Pubitemid 47214568)
10. Rama I, Grinyò JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6:511-9.
11. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 2011;93:294-300.
12. Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res. 2007;13:6247-51. (Pubitemid 350075011)
13. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer. 2003;89:1345-51. (Pubitemid 37363427)
14. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-74. (Pubitemid 37279849)
15. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets. 2007;7:31-40. (Pubitemid 46345506)
16. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21:1105-11.
17. Cvetanovich GL, Hafler DA. Human regulatory T cells in autoimmune diseases. Curr Opin Immunol. 2010;22:753-60.
18. Buckner JH. Mechanisms of impaired regulation by CD4+CD25 +FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10:849-59.
19. Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol. 2007;3:619-26.
20. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-11. (Pubitemid 44154611)
21. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011;11:119-30.
22. Fujio K, Okamura T, Yamamoto K. The family of IL-10-secreting CD4+ T cells. Adv Immunol. 2010;105:99-130.
23. Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to their clinical application. Semin Immunol. 2006;18:120-7. (Pubitemid 43248740)
24. Faria AM, Weiner HL. Oral tolerance and TGF-beta-producing cells. Inflamm Allergy Drug Targets. 2006;5:179-90.
25. Filaci G, Fenoglio D, Indiveri F. CD8+ T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity. 2011;44:51-7.
26. Miyara M, Sakaguchi S. Human Foxp3+CD4+ regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011;89:346-51.
27. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3+CD4+CD25+ regulatory T cells are not mirror images of each other. Trends Immunol. 2008;29:429-35.
28. Lin Ling K, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colon cancer patients. Cancer Immunity. 2007;7:7.
29. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006;177:7398-405. (Pubitemid 44715110)
30. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92:913-20. (Pubitemid 40462639)
31. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-12. (Pubitemid 36182591)
32. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9:4404-8. (Pubitemid 37248397)
33. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-61. (Pubitemid 34921025)
34. Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005;14:1269-73.
35. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, et al. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007;13:2714-21. (Pubitemid 46788040)
36. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65:2457-64. (Pubitemid 40490158)
37. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766-72. (Pubitemid 32691889)
38. highFoxp3+ regulatory T cells in patients with multiple myeloma. Blood. 2006;107:3940-9. (Pubitemid 43726800)
39. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15:3325-32.
40. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs. 2007;8:1002-8. (Pubitemid 350224326)
41. Chan YH. Biostatistics 203. Survival analysis. Singapore Med J. 2004;45:249-56. (Pubitemid 38843332)
42. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of Foxp3+ regulatory T cells in human colorectal cancer. J Transl Med. 2006;4:52.
43. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating Foxp3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186-92.
44. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector CD3+/regulatory (Foxp3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009;137:1270-9.
45. Correale P, Rotundo MS, Del Vecchio MT, Remondo C, Migali C, Ginanneschi C, et al. Regulatory (Foxp3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010;33:435-41.